0.79
-0.0707(-8.20%)
Currency In USD
| Previous Close | 0.86 |
| Open | 0.87 |
| Day High | 0.87 |
| Day Low | 0.77 |
| 52-Week High | 3.25 |
| 52-Week Low | 0.4 |
| Volume | 372,164 |
| Average Volume | 1.63M |
| Market Cap | 128.49M |
| PE | -0.83 |
| EPS | -0.95 |
| Moving Average 50 Days | 0.83 |
| Moving Average 200 Days | 0.92 |
| Change | -0.07 |
If you invested $1000 in Renovaro Biosciences Inc. (RENB) since IPO date, it would be worth $134.1 as of March 14, 2025 at a share price of $0.791. Whereas If you bought $1000 worth of Renovaro Biosciences Inc. (RENB) shares 5 years ago, it would be worth $380.38 as of March 14, 2025 at a share price of $0.791.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
GlobeNewswire Inc.
Mar 03, 2025 2:15 PM GMT
Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States Renovaro’s Strategic Acquisition of BioSymetrics
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
GlobeNewswire Inc.
Feb 26, 2025 6:25 PM GMT
Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a Te
Renovaro Announces $15 million in Equity Committed
GlobeNewswire Inc.
Feb 26, 2025 2:15 PM GMT
LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announces that it has $15 million in additional equity committed at a price per